Deals & Corporate Governance

  • June 29, 2026

    Asthma Drug Developer To Wind Down In Chancery Court

    A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.

  • June 26, 2026

    Wash. Healthcare Firm's Ex-CEO Admits To Embezzling $24M

    A former chief executive officer of Washington-based Community Clinic Network has pled guilty to wire fraud in Washington federal court, admitting he drained almost $24.4 million from the healthcare company's coffers, most of which he lost in a series of poor investment decisions.

  • June 26, 2026

    Taxation With Representation: Sidley, Paul Weiss, Kirkland

    In this week's Taxation With Representation, Germany's Merck KGaA acquires life sciences tools supplier Bio-Techne Corp., drugmaker AbbVie buys clinical-stage biotechnology company Apogee Therapeutics, and building materials supplier CRH acquires infrastructure products maker Arcosa Inc.

  • June 25, 2026

    4th Circ. Says Supply Co.'s Foreign Member Kills Diversity

    The Fourth Circuit on Thursday declined to reinstate a medical supply company's contract dispute against a U.K. corporation over COVID-19 test kits, after finding that the lack of a U.S. citizen on the supply company's side destroys the court's diversity jurisdiction to hear the case.  

  • June 24, 2026

    11th Circ. Urged To Toss Convictions In $1.4B Hospital Fraud

    Two brothers convicted in a $1.4 billion scheme to bill insurers inflated rates for drug tests told the Eleventh Circuit on Wednesday that there was insufficient evidence to support their convictions and that they should have been allowed an evidentiary hearing after potential juror misconduct emerged following the trial.

  • June 22, 2026

    Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal

    Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.

  • June 22, 2026

    FTC Requires Fix For Aurobindo's $250M Lannett Deal

    The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.

  • June 22, 2026

    Sorrento RICO Case Naming Jackson Walker Gets Axed

    A Texas bankruptcy judge blocked a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection in an "ethically compromised" bankruptcy court, ruling the suit's claims are barred by Sorrento's bankruptcy plan.

  • June 18, 2026

    Goodwin, Latham Lead Biotech Kardigan's $400M IPO

    Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.

  • June 16, 2026

    Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics

    Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties. 

  • June 16, 2026

    Capital Markets Attys See Steady Momentum For Biotech IPOs

    Attorneys that helped guide this year’s string of biotech IPOs expect the fast pace of public offerings to continue.

  • June 12, 2026

    Taxation With Representation: Gibson Dunn, Davis Polk, S&C

    In this week's Taxation With Representation, SpaceX prices a $75 billion initial public offering at its designated price range, Apollo Global Management leads a capital commitment for a Broadcom initiative to build artificial intelligence infrastructure for companies including Anthropic, and pharma giant GSK acquires cancer therapy specialist Nuvalent.

  • June 11, 2026

    Cancer Diagnostics Firm Ignite Inks $150M SPAC Merger

    Precision oncology startup Ignite Proteomics LLC will merge with special purpose acquisition company Copley Acquisition Corp. in a deal valuing Ignite at a pro forma enterprise value of $150 million, the companies announced Thursday.

  • June 10, 2026

    Judge Won't Certify Class Of Health Workers In No-Poach Suit

    An Illinois federal judge on Wednesday refused to certify a class of former healthcare employees claiming that their wages were suppressed by alleged no-poach agreements among DaVita, UnitedHealth Group's Surgical Care Affiliates and Tenet Healthcare Corp. unit United Surgical Partners International, ruling that the proposed class is too diverse.

  • June 10, 2026

    Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout

    An investor of rare disease treatment company Catalyst Pharmaceuticals Inc. is attempting to stop a buyout by Italian rival Angelini Pharma SpA, saying Catalyst's deficient proxy statement omits relevant information regarding potential conflicts in the proposed transaction.

  • June 10, 2026

    Molina Says Its Warnings Doom Suit Over Guidance Cuts

    Health insurance provider Molina Healthcare and two of its executives urged a California federal court to dismiss a shareholder suit accusing them of misleading investors about medical costs and internal controls before repeatedly slashing the company's 2025 earnings guidance, arguing that the nature of its business makes costs unpredictable.

  • June 10, 2026

    $25M Patent Verdict Against Ferring Backed By Del. Court

    Swiss drugmaker Ferring Pharmaceuticals Inc. on Wednesday lost its bid to dodge a $25 million verdict in a Delaware federal court patent case over an experimental enema used to treat a particularly deadly form of diarrhea.

  • June 10, 2026

    Acadia Pharma Must Face Investors' Drug Approval Claims

    Acadia Pharmaceuticals must face investors' class action claims it misstated the likelihood that it would get regulatory approval to market its psychosis drug pimavanserin for expanded use, a California federal judge determined, finding a key question about a regulator's directions should be decided by a jury.

  • June 09, 2026

    McKesson, Rite Aid Trust Clash Over Ch. 11 Claims Transfer

    McKesson locked horns Tuesday in New Jersey bankruptcy court with a trust created by Rite Aid's first Chapter 11 plan over whether the medication supplier must hand over antitrust claims against pharmaceutical companies.

  • June 09, 2026

    Novanta Buys Riverpoint In $1.45B Deal Steered By 3 Firms

    Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.

  • June 09, 2026

    The Law360 400: A Look At The Top 100 Firms

    The race to build the legal industry's largest law firm accelerated in 2025, with major firms leaning on mergers, lateral hiring and strategic expansion to climb the ranks of the Law360 400.

  • June 09, 2026

    Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal

    Pharma giant GSK PLC said Tuesday that it has agreed to acquire cancer therapy specialist Nuvalent Inc. for $10.6 billion as it seeks to accelerate its "rapid expansion" into the oncology market.

  • June 05, 2026

    Texas Ex-Hospital Owner Opposes Ch. 7 Conversion Bid

    Texas' bankrupt former hospital owner Sherman/Grayson Hospital LLC said that professional fees have been paid, monthly operating reports filed and other steps taken that should prevent its Chapter 11 case from being converted to a Chapter 7 liquidation.

  • June 05, 2026

    Fed. Circ. Backs Melinta Patent Win In Injections Case

    Nexus Pharmaceuticals lost its appeal of an Illinois federal judge's finding that it infringed a pair of patents relating to a line of injections that treat infections, after the Federal Circuit on Friday shot down the drugmaker's challenge to the lower court's interpretation of key patent terms.

  • June 04, 2026

    GAO Finds Incomplete Data Over DOD's Civilian Medical Ties

    The U.S. Government Accountability Office said Thursday that the U.S. Department of Defense's health agency hasn't sufficiently kept track of DOD partnerships with civilian medical facilities, thus impairing its ability to evaluate those partnerships and further reduce costs.

Expert Analysis

  • Texas Med Spas Must Prepare For 2 New State Laws

    Author Photo

    Two new laws in Texas — regulating elective intravenous therapy and reforming healthcare noncompetes — mark a pivotal shift in the regulatory framework for medical spas in the state, which must proactively adapt their operations and contractual practices, says Brad Cook at Munsch Hardt.

  • Strategies For Cos. Navigating US-Indian Pharma Partnerships

    Author Photo

    Recent policy adjustments implemented by the U.S. government present both new opportunities and heightened regulatory scrutiny for the Indian life sciences industry, amplifying the importance of collaboration between the Indian and U.S. pharmaceutical sectors, say Bryant Godfrey at Foley Hoag and Jashaswi Ghosh at Holon Law Partners.

  • A Look At Key 5th Circ. White Collar Rulings So Far This Year

    Author Photo

    In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker.

  • A Look At Trump 2.0 Antitrust Enforcement So Far

    Author Photo

    The first six months of President Donald Trump's second administration were marked by aggressive antitrust enforcement tempered by traditional structural remedies for mergers, but other unprecedented actions, like the firing of Federal Trade Commission Democrats, will likely stoke heated discussion ahead, says Richard Dagen at Axinn.

  • Plan For Increased HSR Info Sharing With Wash. Antitrust Law

    Author Photo

    Washington's merger notification requirements, effective later this month, combined with the Federal Trade Commission's new Hart-Scott-Rodino Act rules, will result in greater information sharing among state and federal agencies, making it important for merging parties to consider their transaction's potential state antitrust implications early on, say attorneys at McDermott.

  • Spinoff Transaction Considerations For Biotech M&A

    Author Photo

    Amid current market challenges, boards and management teams of biotech companies can consider several strategies for maximizing value should a spinoff opportunity arise, but not without significant advance planning and careful implementation, particularly in cases that might qualify as tax-free, say attorneys at Paul Hastings.

  • How Ore. Law Puts New Confines On Corp. Health Ownership

    Author Photo

    A newly enacted law in Oregon strengthens the state’s restrictions on corporate ownership of healthcare practices, with new limitations on overlapping control, permissible services, restrictive covenants and more making it necessary for practices to review decades-old physician practice arrangements, say attorneys at Ropes & Gray.

  • Trump Antitrust Shift Eases Pressure On Private Equity Deals

    Author Photo

    Enforcement actions and statements by Trump administration antitrust officials forecast a shift away from specifically targeting private equity activity, which should be welcome news to dealmakers, but firms shouldn't expect to escape traditional antitrust scrutiny, says Nathaniel Bronstein at Fried Frank.

  • How Trump Administration's Antitrust Agenda Is Playing Out

    Author Photo

    Under the current antitrust agency leadership, the latest course in merger enforcement, regulatory approach and key sectors shows a marked shift from Biden-era practices and includes a return to remedies and the commitment to remain focused on the bounds of U.S. law, say attorneys at Wilson Sonsini.

  • Why Texas Should Slow Down On Healthcare Merger Bills

    Author Photo

    More time is needed to study three Texas bills aimed at considering the effects of healthcare consolidation to increase affordability and access to healthcare, which could have the opposite effect, say John Saran and Harshita Rathore at Holland & Knight and Robbie Allen at U.S. Heart and Vascular.

  • Navigating The Expanding Frontier Of Premerger Notice Laws

    Author Photo

    Washington's newly enacted law requiring premerger notification to state enforcers builds upon a growing trend of state scrutiny into transactions in the healthcare sector and beyond, and may inspire other states to enact similar legislation, say attorneys at Simpson Thacher.

  • Issues To Watch At ABA's Antitrust Spring Meeting

    Author Photo

    Attorneys at Freshfields consider the future of antitrust law and competition enforcement amid agency leadership changes and other emerging developments likely to dominate discussion at the American Bar Association's Antitrust Spring Meeting this week.

  • Reviewing Calif. Push To Restrict Private Equity In Healthcare

    Author Photo

    A recent proposed bill in California aims to broaden the state's existing corporate practice of medicine restrictions, so investors must ensure that there is clear delineation between private equity investment in practice management and physicians' clinical decision-making, say attorneys at Debevoise.